Michael Bigham Paratek Pharmaceuticals, Inc. (PRTK) insider trading activity

Michael Bigham is Exec. Chairman of the Board of Paratek Pharmaceuticals, Inc.. Currently has a direct ownership of 0 shares of PRTK, which is worth approximately $0. The most recent transaction as insider was on Sep 21, 2023, when has been sold 1,358,032 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

0% 12M change

Total Value Held $0

MICHAEL BIGHAM Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Sep 21 2023	SELL Sale (or disposition) back to the issuer	-	1,358,032 Reduced 100.0%	0 Common Stock
Aug 09 2023	SELL Open market or private sale	$68,750 $2.2 p/Share	31,250 Reduced 2.29%	1,334,702 Common Stock
Aug 08 2023	BUY Grant, award, or other acquisition	-	156,250 Added 10.26%	1,365,952 Common Stock
Dec 21 2022	SELL Open market or private sale	$31,342 $1.99 p/Share	15,750 Reduced 1.29%	1,209,702 Common Stock
Dec 20 2022	BUY Grant, award, or other acquisition	-	45,000 Added 3.54%	1,225,452 Common Stock
Dec 13 2022	SELL Open market or private sale	$62,506 $1.96 p/Share	31,891 Reduced 2.63%	1,180,452 Common Stock
Dec 12 2022	SELL Open market or private sale	$38,578 $1.98 p/Share	19,484 Reduced 1.58%	1,212,343 Common Stock
Oct 28 2022	SELL Open market or private sale	$20,820 $3.47 p/Share	6,000 Reduced 0.48%	1,231,827 Common Stock
Oct 25 2022	BUY Grant, award, or other acquisition	-	30,000 Added 2.37%	1,237,827 Common Stock
Aug 09 2022	SELL Open market or private sale	$76,174 $2.66 p/Share	28,637 Reduced 2.32%	1,207,827 Common Stock
Aug 08 2022	BUY Grant, award, or other acquisition	-	143,182 Added 10.38%	1,236,464 Common Stock
Mar 15 2022	BUY Grant, award, or other acquisition	-	202,500 Added 15.63%	1,093,282 Common Stock
Dec 15 2021	SELL Open market or private sale	$76,087 $4.27 p/Share	17,819 Reduced 1.96%	890,782 Common Stock
Dec 14 2021	SELL Open market or private sale	$37,678 $4.37 p/Share	8,622 Reduced 0.94%	908,601 Common Stock
Dec 13 2021	SELL Open market or private sale	$22,361 $4.42 p/Share	5,059 Reduced 0.55%	917,223 Common Stock
Aug 17 2021	SELL Open market or private sale	$163,994 $5.12 p/Share	32,030 Reduced 3.36%	922,282 Common Stock
Aug 16 2021	BUY Grant, award, or other acquisition	-	75,000 Added 7.29%	954,312 Common Stock
Jun 04 2021	SELL Open market or private sale	$333,331 $9.7 p/Share	34,364 Reduced 3.76%	879,312 Common Stock
May 27 2021	BUY Grant, award, or other acquisition	-	85,909 Added 8.59%	913,676 Common Stock
Mar 30 2021	BUY Grant, award, or other acquisition	-	281,250 Added 25.36%	827,767 Common Stock
Dec 14 2020	SELL Open market or private sale	$174,883 $6.71 p/Share	26,063 Reduced 4.55%	546,517 Common Stock
Dec 11 2020	SELL Open market or private sale	$127,442 $6.95 p/Share	18,337 Reduced 3.1%	572,580 Common Stock
Nov 13 2020	SELL Open market or private sale	$155,662 $5.93 p/Share	26,250 Reduced 4.25%	590,917 Common Stock
Nov 12 2020	BUY Grant, award, or other acquisition	-	75,000 Added 10.84%	617,167 Common Stock
Feb 02 2018	BUY Exercise of conversion of derivative security	$99,996 $4.3 p/Share	23,255 Added 1.68%	1,358,032 Common Stock

Also insider at

FLAC

Frazier Lifesciences Acquisition Corp Financial Services

Director

Michael Bigham

Exec. Chairman of the Board

Boston, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PRTK shares.

Notify only if

Value

Insider Trading

Get notified when an Paratek Pharmaceuticals, Inc. insider buys or sells PRTK shares.

Notify only if

Operation

Value

Type

News

Receive news related to Paratek Pharmaceuticals, Inc.

Track Activities on PRTK

Account